Sun Pharma falls nearly 2% as Ilumya worries weigh
In short
Sun Pharma’s shares fell nearly 2% in trading. The stock had seen more than 23 lakh shares worth ₹407 crore change hands, and the 52-week high was ₹2,046.90 in July.
The fall matters because analysts appear to be worried about Ilumya. The reporting does not say exactly how estimates changed or whether the pressure will last.
What the reporting says
Sun Pharma’s stock fell nearly 2% in session trade as concerns around Ilumya weighed on analyst estimates, according to the headline and market summary. The stock had traded over 23 lakh shares worth ₹407 crore in the session, against a 52-week high of ₹2,046.90 in July. The immediate impact is weaker sentiment on the counter, while the precise estimate changes were not provided.
Why it matters
Sun Pharma’s stock slipped nearly 2% in the session, with more than 23 lakh shares worth ₹407 crore traded, according to the market summary. The report links the decline to concerns around Ilumya affecting analyst estimates, but it does not specify what part of the forecast changed. The move is relevant to equity investors in Sun Pharma and the broader pharma sector, though the depth of the impact is unclear.